Planck 2015 results I. Overview of products and scientific results

The European Space Agency's Planck satellite, which is dedicated to studying the early Universe and its subsequent evolution, was launched on 14 May 2009. It scanned the microwave and submillimetre sky continuously between 12 August 2009 and 23 October 2013. In February 2015, ESA and the Planck Collaboration released the second set of cosmology products based on data from the entire Planck mission, including both temperature and polarization, along with a set of scientific and technical papers and a web-based explanatory supplement. This paper gives an overview of the main characteristics of the data and the data products in the release, as well as the associated cosmological and astrophysical science results and papers. The data products include maps of the cosmic microwave background (CMB), the thermal Sunyaev-Zeldovich effect, diffuse foregrounds in temperature and polarization, catalogues of compact Galactic and extragalactic sources (including separate catalogues of Sunyaev-Zeldovich clusters and Galactic cold clumps), and extensive simulations of signals and noise used in assessing uncertainties and the performance of the analysis methods. The likelihood code used to assess cosmological models against the Planck data is described, along with a CMB lensing likelihood. Scientific results include cosmological parameters derived from CMB power spectra, gravitational lensing, and cluster counts, as well as constraints on inflation, non-Gaussianity, primordial magnetic fields, dark energy, and modified gravity, and new results on low-frequency Galactic foregrounds

Comparison of Sunyaev-Zel’dovich measurements from Planck and from the Arcminute Microkelvin Imager for 99 galaxy clusters

We present observations and analysis of a sample of 123 galaxy clusters from the 2013 Planck catalogue of Sunyaev-Zel’dovich sources with the Arcminute Microkelvin Imager (AMI), a ground-based radio interferometer. AMI provides an independent measurement with higher angular resolution, 3 arcmin compared to the Planck beams of 5–10 arcmin. The AMI observations thus provide validation of the cluster detections, improved positional estimates, and a consistency check on the fitted ‘size’ (θ_s) and ‘flux’ (Y_tot) parameters in the Generalised Navarro, Frenk and White (GNFW) model. We detect 99 of the clusters. We use the AMI positional estimates to check the positional estimates and error-bars produced by the Planck algorithms PowellSnakes and MMF3. We find that Y_tot values as measured by AMI are biased downwards with respect to the Planck constraints, especially for high Planck-SNR clusters. We perform simulations to show that this can be explained by deviation from the ‘universal’ pressure profile shape used to model the clusters. We show that AMI data can constrain the α and β parameters describing the shape of the profile in the GNFW model for individual clusters provided careful attention is paid to the degeneracies between parameters, but one requires information on a wider range of angular scales than are present in AMI data alone to correctly constrain all parameters simultaneously.The AMI telescope is supported by Cambridge University. YCP and CR acknowledge support from CCT/Cavendish Laboratory and STFC studentships, respectively. YCP and MO acknowledge support from Research Fellowships from Trinity College and Sidney Sussex College, Cambridge, respectively. This work was partially undertaken on the COSMOS Shared Memory system at DAMTP, University of Cambridge operated on behalf of the STFC DiRAC HPC Facility. This equipment is funded by BIS National E-infrastructure capital grant ST/J005673/1 and STFC grants ST/H008586/1, ST/K00333X/1. CM acknowledges her KICC Fellowship grant funding for the procurement of the cluster used for computational work. In addition, we would like to thank the IOA computing support team for maintaining the cluster.This is the final version of the article. It first appeared from the European Southern Observatory (ESO) via http://dx.doi.org/10.1051/0004-6361/20142418

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

Abstract BACKGROUND: Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis. METHODS: We concluded a randomized trial involving 1088 patients with multiple sclerosis, 18 to 55 years of age, with a score of 0 to 5.5 on the Expanded Disability Status Scale and at least one relapse in the previous year or at least two relapses in the previous 2 years. Patients were randomly assigned (in a 1:1:1 ratio) to placebo, 7 mg of teriflunomide, or 14 mg of teriflunomide once daily for 108 weeks. The primary end point was the annualized relapse rate, and the key secondary end point was confirmed progression of disability for at least 12 weeks. RESULTS: Teriflunomide reduced the annualized relapse rate (0.54 for placebo vs. 0.37 for teriflunomide at either 7 or 14 mg), with relative risk reductions of 31.2% and 31.5%, respectively (P<0.001 for both comparisons with placebo). The proportion of patients with confirmed disability progression was 27.3% with placebo, 21.7% with teriflunomide at 7 mg (P=0.08), and 20.2% with teriflunomide at 14 mg (P=0.03). Both teriflunomide doses were superior to placebo on a range of end points measured by magnetic resonance imaging (MRI). Diarrhea, nausea, and hair thinning were more common with teriflunomide than with placebo. The incidence of elevated alanine aminotransferase levels ( 651 times the upper limit of the normal range) was higher with teriflunomide at 7 mg and 14 mg (54.0% and 57.3%, respectively) than with placebo (35.9%); the incidence of levels that were at least 3 times the upper limit of the normal range was similar in the lower- and higher-dose teriflunomide groups and the placebo group (6.3%, 6.7%, and 6.7%, respectively). Serious infections were reported in 1.6%, 2.5%, and 2.2% of patients in the three groups, respectively. No deaths occurred. CONCLUSIONS: Teriflunomide significantly reduced relapse rates, disability progression (at the higher dose), and MRI evidence of disease activity, as compared with placebo. (Funded by Sanofi-Aventis; TEMSO ClinicalTrials.gov number, NCT00134563.)

Randomized trial of oral teriflunomide for relapsing multiple sclerosis

Teriflunomide is a new oral disease-modifying therapy for relapsing forms of multiple sclerosis